Expression of TAG-72 in ovarian cancer and its correlation with tumor stage and patient prognosis

Cancer Letters

Volumn 251, Issue 2, 2007, Pages 247-257

  Ponnusamy, Moorthy P ^a   Venkatraman, Ganesh ^a   Singh, Ajay P ^a   Chauhan, Subhash C ^a   Johansson, Sonny L ^a   Jain, Maneesh ^a   Smith, Lynnette ^b   Davis, John S ^a,b   Remmenga, Steven W ^a   Batra, Surinder K ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Diagnosis; Ovarian cancer; Prognosis; TAG 72; Therapy

Indexed keywords

GLYCOPROTEIN; MONOCLONAL ANTIBODY CC49; PROTEIN TAG 72; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; BINDING AFFINITY; CANCER CLASSIFICATION; CANCER STAGING; CANCER SURVIVAL; CELL MEMBRANE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KAPLAN MEIER METHOD; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION;

ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL MEMBRANE; CYTOPLASM; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 34247618735     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.11.025     Document Type: Article

References (43)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., and Thun M.J. Cancer statistics, 2006. CA Cancer J. Clin. 56 (2006) 106-130
2. Auersperg N., Edelson M.I., Mok S.C., Johnson S.W., and Hamilton T.C. The biology of ovarian cancer. Semin. Oncol. 25 (1998) 281-304
3. Auersperg N., Wong A.S., Choi K.C., Kang S.K., and Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22 (2001) 255-288
4. exander-Sefre F., Menon U., and Jacobs I.J. Ovarian cancer screening. Hosp. Med. 63 (2002) 210-213
5. Ozols R.F. Update on the management of ovarian cancer. Cancer J. 8 Suppl (2002) S22-S30
6. Bast Jr. R.C. Status of tumor markers in ovarian cancer screening. J. Clin. Oncol. 21 (2003) 200-205
7. Jacobs I.J., and Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol. Cell Proteomics 3 (2004) 355-366
8. Menon U., and Jacobs I.J. Recent developments in ovarian cancer screening. Curr. Opin. Obstet. Gynecol. 12 (2000) 39-42
9. Menon U., and Jacobs I. Screening for ovarian cancer. Best Pract. Res. Clin. Obstet. Gynaecol. 16 (2002) 469-482
10. Fritsche H.A., and Bast R.C. CA 125 in ovarian cancer: advances and controversy. Clin. Chem. 44 (1998) 1379-1380
11. Bast Jr. R.C., Xu F.J., Yu Y.H., Barnhill S., Zhang Z., and Mills G.B. CA 125: the past and the future. Int. J. Biol. Markers 13 (1998) 179-187
12. Jacobs I.J., Oram D.H., and Bast Jr. R.C. Strategies for improving the specificity of screening for ovarian cancer with tumor-associated antigens CA 125, CA 15-3, and TAG 72.3. Obstet. Gynecol. 80 (1992) 396-399
13. Thor A., Ohuchi N., Szpak C.A., Johnston W.W., and Schlom J. Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. Cancer Res. 46 (1986) 3118-3124
14. Thor A., Viglione M.J., Muraro R., Ohuchi N., Schlom J., and Gorstein F. Monoclonal antibody B72.3 reactivity with human endometrium: a study of normal and malignant tissues. Int. J. Gynecol. Pathol. 6 (1987) 235-247
15. Colcher D., Hand P.H., Nuti M., and Schlom J. A spectrum of monoclonal antibodies reactive with human mammary tumor cells. Proc. Natl. Acad. Sci. USA 78 (1981) 3199-3203
16. Colcher D., Minelli M.F., Roselli M., Muraro R., Simpson-Milenic D., and Schlom J. Radioimmunolocalization of human carcinoma xenografts with B72.3 second generation monoclonal antibodies. Cancer Res. 48 (1988) 4597-4603
17. Colcher D.M., Milenic D.E., and Schlom J. Generation and characterization of monoclonal antibody B72.3. Experimental and preclinical studies. Target. Diagn.Ther. 6 (1992) 23-44
18. Johnston W.W., Szpak C.A., Lottich S.C., Thor A., and Schlom J. Use of a monoclonal antibody (B72.3) as a novel immunohistochemical adjunct for the diagnosis of carcinomas in fine needle aspiration biopsy specimens. Hum. Pathol. 17 (1986) 501-513
19. Batra S.K., Jain M., Wittel U.A., Chauhan S.C., and Colcher D. Pharmacokinetics and biodistribution of genetically engineered antibodies. Curr. Opin. Biotechnol. 13 (2002) 603-608
20. Meredith R.F., Bueschen A.J., Khazaeli M.B., Plott W.E., Grizzle W.E., Wheeler R.H., Schlom J., Russell C.D., Liu T., and LoBuglio A.F. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. J. Nucl. Med. 35 (1994) 1017-1022
21. Meredith R.F., Partridge E.E., Alvarez R.D., Khazaeli M.B., Plott G., Russell C.D., Wheeler R.H., Liu T., Grizzle W.E., Schlom J., and LoBuglio A.F. Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. J. Nucl. Med. 37 (1996) 1491-1496
22. Robert F., Busby E.M., and LoBuglio A.F. Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: clinical effects and hematologic toxicity. Cancer Biother. Radiopharm. 18 (2003) 317-325
23. Hanisch F.G., Uhlenbruck G., Egge H., and Peter-Katalinic J. A B72.3 second-generation-monoclonal antibody (CC49) defines the mucin-carried carbohydrate epitope Gal beta(1-3) [NeuAc alpha(2-6)]GalNAc. Biol. Chem. Hoppe Seyler 370 (1989) 21-26
24. Silverman H.S., Sutton-Smith M., McDermott K., Heal P., Leir S.H., Morris H.R., Hollingsworth M.A., Dell A., and Harris A. The contribution of tandem repeat number to the O-glycosylation of mucins. Glycobiology 13 (2003) 265-277
25. Chauhan S.C., Jain M., Moore E.D., Wittel U.A., Li J., Gwilt P.R., Colcher D., and Batra S.K. Pharmacokinetics and biodistribution of 177Lu-labeled multivalent single-chain Fv construct of the pancarcinoma monoclonal antibody CC49. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 264-273
26. Goel A., Colcher D., Baranowska-Kortylewicz J., Augustine S., Booth B.J., Pavlinkova G., and Batra S.K. Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. 60 (2000) 6964-6971
27. Kashmiri S.V., Shu L., Padlan E.A., Milenic D.E., Schlom J., and Hand P.H. Generation, characterization, and in vivo studies of humanized anticarcinoma antibody CC49. Hybridoma 14 (1995) 461-473
28. Larson S.M., El-Shirbiny A.M., Divgi C.R., Sgouros G., Finn R.D., Tschmelitsch J., Picon A., Whitlow M., Schlom J., Zhang J., and Cohen A.M. Single chain antigen binding protein (sFv CC49): first human studies in colorectal carcinoma metastatic to liver. Cancer 80 (1997) 2458-2468
29. Moniaux N., Varshney G.C., Chauhan S.C., Copin M.C., Jain M., Wittel U.A., Andrianifahanana M., Aubert J.P., and Batra S.K. Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans. J. Histochem. Cytochem. 52 (2004) 253-261
30. Singh A.P., Moniaux N., Chauhan S.C., Meza J.L., and Batra S.K. Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis. Cancer Res. 64 (2004) 622-630
31. Filella X., Friese S., Roth H.J., Nussbaum S., and Wehnl B. Technical performance of the Elecsys CA 72-4 test-development and field study. Anticancer Res. 20 (2000) 5229-5232
32. Kelly F.J., Miller C.R., Buchsbaum D.J., Gomez-Navarro J., Barnes M.N., Alvarez R.D., and Curiel D.T. Selectivity of TAG-72-targeted adenovirus gene transfer to primary ovarian carcinoma cells versus autologous mesothelial cells in vitro. Clin. Cancer Res. 6 (2000) 4323-4333
33. Alvarez R.D., Huh W.K., Khazaeli M.B., Meredith R.F., Partridge E.E., Kilgore L.C., Grizzle W.E., Shen S., Austin J.M., Barnes M.N., Carey D., Schlom J., and LoBuglio A.F. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 8 (2002) 2806-2811
34. Bell J., Mojzisik C., Hinkle Jr. G., Derman H., Schlom J., and Martin E. Intraoperative radioimmunodetection of ovarian cancer using monoclonal antibody B72.3 and a portable gamma-detecting probe. Obstet. Gynecol. 76 (1990) 607-611
35. McIntosh D.G., Colcher D., Seemayer T., and Smith M.L. The intraoperative detection of ovarian adenocarcinoma using radiolabeled CC49 monoclonal antibody and a hand-held gamma-detecting probe. Cancer Biother. Radiopharm. 12 (1997) 287-294
36. Chhieng D.C., Rodriguez-Burford C., Talley L.I., Sviglin H., Stockard C.R., Kleinberg M.J., Barnes M.N., Partridge E.E., Khazaeli M.B., and Grizzle W.E. Expression of CEA, Tag-72, and Lewis-Y antigen in primary and metastatic lesions of ovarian carcinoma. Hum. Pathol. 34 (2003) 1016-1021
37. Thor A., Gorstein F., Ohuchi N., Szpak C.A., Johnston W.W., and Schlom J. Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. J. Natl. Cancer Inst. 76 (1986) 995-1006
38. Alvarez R.D., Partridge E.E., Khazaeli M.B., Plott G., Austin M., Kilgore L., Russell C.D., Liu T., Grizzle W.E., Schlom J., LoBuglio A.F., and Meredith R.F. Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. Gynecol. Oncol. 65 (1997) 94-101
39. Meredith R.F., Khazaeli M.B., Plott W.E., Grizzle W.E., Liu T., Schlom J., Russell C.D., Wheeler R.H., and LoBuglio A.F. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer. Clin. Cancer Res. 2 (1996) 1811-1818
40. Muraro R., Kuroki M., Wunderlich D., Poole D.J., Colcher D., Thor A., Greiner J.W., Simpson J.F., Molinolo A., and Noguchi P. Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen. Cancer Res. 48 (1988) 4588-4596
41. McGuckin M.A., Walsh M.D., Hohn B.G., Ward B.G., and Wright R.G. Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum. Pathol. 26 (1995) 432-439
42. Rosen D.G., Yang G., Cai K.Q., Bast Jr. R.C., Gershenson D.M., Silva E.G., and Liu J. Subcellular localization of p27kip1 expression predicts poor prognosis in human ovarian cancer. Clin. Cancer Res. 11 (2005) 632-637
43. Ueda S., Ogata S., Tsuda H., Kawarabayashi N., Kimura M., Sugiura Y., Tamai S., Matsubara O., Hatsuse K., and Mochizuki H. The correlation between cytoplasmic overexpression of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 29 (2004) e1-e8